Literature DB >> 19216210

Hypnotherapy as an adjuvant for the management of inflammatory bowel disease: a case report.

Mohammad Hassan Emami1, Ali Gholamrezaei, Houshang Daneshgar.   

Abstract

Idiopathic inflammatory bowel diseases (IBDs) significantly affect the quality of life of sufferers. Improved quality of life and patient symptom management may be achieved through integrating psychological/behavioral interventions with pharmacologic treatments. Here is our experience with hypnotherapy as an adjuvant management for an 18-year-old female with Crohn's Disease (CD) in remission (patient I) and a 24-year-old female with CD in active phase (patient II). The patients participated in 12 weekly one-hour sessions of hypnotherapy. Gut-directed, ego-strengthening, and post-hypnotic suggestions and immune-directed imaginations were used. After the hypnotherapy course, symptoms, psychological state, and quality of life improved in patient I, but not patient II (according to questionnaires). After a 6 month follow-up, symptoms and quality of life were the same as at the end of hypnotherapy sessions in both patients. The patients reported the greatest benefit of hypnotherapy was in helping them to cope better with their disease and also in improving their psychological state. Hypnotherapy may improve quality of life of IBD patients in remission and help them to cope better with their disease. Well-designed controlled clinical trials are needed in this field.

Entities:  

Mesh:

Year:  2009        PMID: 19216210     DOI: 10.1080/00029157.2009.10401675

Source DB:  PubMed          Journal:  Am J Clin Hypn        ISSN: 0002-9157


  2 in total

1.  Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis.

Authors:  L Keefer; T H Taft; J L Kiebles; Z Martinovich; T A Barrett; O S Palsson
Journal:  Aliment Pharmacol Ther       Date:  2013-08-19       Impact factor: 8.171

2.  Pain management in patients with inflammatory bowel disease: insights for the clinician.

Authors:  Arvind Iyengar Srinath; Chelsea Walter; Melissa C Newara; Eva M Szigethy
Journal:  Therap Adv Gastroenterol       Date:  2012-09       Impact factor: 4.409

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.